Moderna, Inc. MRNA shares are getting hit because of a bad earnings report. The Street didn't like the numbers. The shares have broken a support level and may form a new downtrend. This is why Moderna is our Stock of the Day. If a stock is trending lower, there is more supply than demand. There aren't enough buy orders to absorb all of the sell orders. The market is out of equilibrium. If the stock reaches support, the dynamics change. There is enough demand to absorb the supply. For every sell order, there ...

Moderna Inc. (NASDAQ:MRNA) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants St??phane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Michael Yee - Jefferies Elliott Bosco - UBS Gena Wang - Barclays Luca Issi - RBC Capital Alexandria Hammond - Bank of America Edward Tenthoff - Pi ...

Second Quarter 2024 Financial Results August 1, 2024 mode © 2024 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expected product sales in 2024 and trends informing Moderna's 2024 sales outlook; Moderna's ability to meet the 2024/2025 respiratory virus season demand and to drive vaccination rates; ...

Moderna, Inc. (MRNA) reported a loss of $3.33 per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $3.47. In the year-ago period, management posted a loss of $3.62. Revenues in the quarter were $241 million, beating the Zacks Consensus Estimate of $124.9 million. Total revenues declined 30% year over year due to reduced COVID-19 vaccine sales during the quarter. Quarter in Detail Product sales, entirely from the sale of COVID-19 vaccines, were down 37% year over year to ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Key Takeaways Moderna lowered its full-year guidance as falling European demand and a difficult U.S. market limited sales of its COVID-19 vaccine. The company reported a second quarter loss and a 30% drop in revenue. The stock tumbled, dropping into negative territory for the year. Moderna (MRNA) shares plunged after the COVID-19 vaccine maker slashed its outlook on lower demand in Europe and a tough market in the U.S. The company now expects full-year product revenue of $3 billion to $3.5 billion, down fro ...

The drugmaker is facing problems in the U.S. and abroad Moderna Inc (NASDAQ:MRNA) stock is freefalling this morning, last seen down 15.2% to trade at $95.48 and pacing for its worst day since November 2021 after the company's second-quarter financial results. The drugmaker reported revenue and losses that beat Wall Street's estimates, but also lowered its full-year sales guidance due to problems stateside and abroad. Specifically, Moderna is facing increased competition for respiratory vaccines in the U.S. ...

Moderna (MRNA) came out with a quarterly loss of $3.33 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.03%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.59 per share when it actually produced a loss of $3.07, delivering a surprise of 14.48%. Over the last four quarters, the company has s ...

The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a "competitive environment" for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 billion, down from a previous guidance of $4 ...

Exhibit 99.1 Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June Announced positive Phase 3 data for combination vaccine against influenza and COVID-19 Announ ...